Zura Bio Ltd (ZURA) Stock Price & Analysis
Zura Bio Ltd (ZURA) fell 1.13% to USD 5.23 as of July 26, 2026 at 08:37 UTC, according to Nexqual real-time market data.
ZURA last closed at USD 5.29; the session ranged USD 5.13–5.48 on volume of 366,205 shares. Market capitalization is $496.23M, with a 52-week range of USD 1.35–7.44 (NCM). Source: Nexqual, July 26, 2026 at 08:37 UTC.
Key Statistics (as of July 26, 2026 at 08:37 UTC)
| Price | USD 5.23 |
|---|---|
| Change | ▼ 1.13% (down) |
| Previous Close | USD 5.29 |
| Open | USD 5.4 |
| Day Range | USD 5.13 – 5.48 |
| 52-Week Range | USD 1.35 – 7.44 |
| Volume | 366,205 shares |
| Market Cap | $496.23M |
| Exchange | NCM |
Technical Analysis (ZURA)
Nexqual's technical model rates ZURA "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 26, 2026 at 08:37 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.93 (neutral) |
| vs SMA50 | Above (USD 4.57) |
| MACD | 0.22 (positive) |
Analyst Ratings (ZURA)
Wall Street analysts rate ZURA "Strong Buy" based on 6 analysts, with a mean price target of USD 15.67 (range USD 11–26), per Nexqual as of July 26, 2026 at 08:37 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 15.67 |
| High Target | USD 26 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (ZURA)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD -0.19 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.22 vs est -0.18 ▼ miss |
| 2025-12-31 | USD -0.49 vs est -0.15 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.18 ▼ miss |
| 2025-06-30 | USD -0.17 vs est -0.18 ▲ beat |
Source: Nexqual, July 26, 2026 at 08:37 UTC.
Financials & Fundamentals (ZURA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -40.96% |
| Current Ratio | 19.33 |
| Total Cash | $225.59M |
| Total Debt | $0 |
| Free Cash Flow | $-46.89M |
Source: Nexqual, July 26, 2026 at 08:37 UTC.
Financial Health Score (ZURA)
Nexqual rates Zura Bio Ltd's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 08:37 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $226M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$73M |
| Efficiency | Critical — ROE -41%, ROA -25.4% |
Ownership (ZURA)
| Insider Ownership | +21.51% |
|---|---|
| Institutional Ownership | +79.07% |
| Shares Outstanding | 94.88M |
| Float | 50.75M |
| Short % of Float | +14.46% |
Source: Nexqual, July 26, 2026 at 08:37 UTC.
Leadership (ZURA)
Zura Bio Ltd is led by Sandeep Chidambar Kulkarni (age 43), Co-Founder, CEO & Director, per Nexqual as of July 26, 2026 at 08:37 UTC.
| Co-Founder, CEO & Director | Sandeep Chidambar Kulkarni (age 43) |
|---|---|
| COO, Chief Legal Officer & Corporate Secretary | Kimberly Ann Davis (age 57) |
| Chief Technology Officer | Gary Whale (age 51) |
Major Backers & Investors (ZURA)
Notable institutional backers of Zura Bio Ltd include Suvretta Capital Management, LLC, Venrock Adviser, LLC, JPMorgan, according to Nexqual as of July 26, 2026 at 08:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.54% |
| Venrock Adviser, LLC | 6.77% |
| JPMorgan | 4.69% |
| Great Point Partners LLC | 4.44% |
| Braidwell LP | 4.2% |
| Siren, L.L.C. | 3.93% |
| Commodore Capital Lp | 3.42% |
| Pfizer Inc | 2.99% |
Source: Nexqual, July 26, 2026 at 08:37 UTC.
From Zura Bio Ltd's Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
- The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
- It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TCRX | TScan Therapeutics, Inc. | USD 0.79 | ▼ 11.78% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
| PEPG | PepGen Inc. | USD 1.93 | ▲ 0.52% |
| ACRV | Acrivon Therapeutics, Inc. | USD 1.6 | ▼ 4.76% |
| TNGX | Tango Therapeutics, Inc. | USD 26.63 | ▼ 5.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:37 UTC. This page is informational and not investment advice.